Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of abemaciclib plus tamoxifen versus abemaciclib alone in previously treated HR-positive, HER2-negative metastatic breast cancer
2016-000288-18Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started May 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000288-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000288-18.